Gilead Sciences (GILD) EPS (Diluted) Growth (1y) (2010 - 2026)
Gilead Sciences (GILD) EPS (Diluted) Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -0.91% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -130.72% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -92.04% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.26% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 64.94% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -640.40% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -108.14% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -69.50% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -90.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -640.40% |
| Mar 31, 2026 | 54.30% |
| Dec 31, 2025 | 41.86% |
| Sep 30, 2025 | 143.58% |
| Jun 30, 2025 | 21.04% |
| Mar 31, 2025 | 131.23% |
| Dec 31, 2024 | 26.15% |
| Sep 30, 2024 | -42.17% |
| Jun 30, 2024 | 56.31% |
| Mar 31, 2024 | -528.64% |
| Dec 31, 2023 | -13.01% |
| Sep 30, 2023 | 22.00% |
| Jun 30, 2023 | -8.31% |
| Mar 31, 2023 | 8,106.50% |
| Dec 31, 2022 | 334.31% |
| Sep 30, 2022 | -30.88% |
| Jun 30, 2022 | -25.18% |
| Mar 31, 2022 | -99.30% |
| Dec 31, 2021 | -75.63% |
| Sep 30, 2021 | 632.00% |